Gianna focuses her practice on corporate and securities law matters for publicly traded and late-stage private companies in the life sciences, medical device, technology, and energy and sustainability industries. Gianna advises companies on SEC reporting and disclosure requirements, stock exchange requirements, and corporate governance and compliance matters. Gianna also has experience with representing issuers and investment banking firms on a variety of transactions, including initial public offerings, follow-on offerings, registered direct offerings, at-the-market offerings, private investments in public equity (PIPEs), and reverse mergers.
viewpoints
Public Benefit Corporations and the SPAC Surge
April 21, 2021 | Blog | By Thomas R. Burton, III, Gianna Nappi
News & Press
Mintz Advises Quaise Energy in $21M Series A1 Funding
March 14, 2024
CAMBRIDGE, Mass.—Mintz advised Quaise Energy, a developer of a new hybrid deep drilling technology for geothermal energy, in its recent $21 million Series A1 funding round. The deal brings Quaise’s total funding to more than $95 million. The investment will be used to scale up Quaise’s supply chain and enhance its field operations by improving geologic understanding at plant sites.
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Recognition & Awards
Phi Beta Kappa